Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2002

Level of antithrombin III, protein C, protein S and other selected parametersof coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis.

Andrzej Swiatkiewicz, Piort Jurkowski, Maria Kotschy, Marek Ciecierski, Arkadiusz Jawień

Med Sci Monit 2002; 8(4): CR263-268 :: ID: 420870

Abstract

BACKGROUND: Thrombophilia is caused mainly by disturbances of hemostasisinvolving excessive coagulation system activation, reduction of anticoagulation system (antithrombinIII, protein C, protein S, RAPC) or fibrinolytic activity. MATERIAL/METHODS: In 34 young patients (aged2 incidents) the activity of antithrombin III, proteinC, S, platelet count, adhesion and aggregation, APTT, stipven-kephalin, prothrombin time and INR wereinvestigated. Fibrinogen, factor XIII, ELT, FDP, Ag t-PA levels, antigen concentration and PAI-1 activitywere determined. Patients with idiopathic DVT, after elimination of most important thromboembolism riskfactors, were qualified for the study. DVT was confirmed in all patients by phlebography, plethysmographyand ultrasonography. Results were compared with a group of 54 healthy controls. RESULTS: In almost 50%of patients with recurrent DVT (15/34) decrease of at least one plasma coagulation inhibitor (AT III,PC, PS) level was observed. In the patient group (with AT III and/or PC and/or PS decrease) statisticallysignificant reduction of kaolin-kephalin time in comparison with controls was observed (α<0. 01). Analysis of fibrinolysis system demonstrated significant factor XIII level decrease (to 58.3&percnt;), fibrinogen level increase, ELT prolongation, and fibrinogen and fibrin degradation product increase in comparison with controls. The patients demonstrated 3-fold higher t-PA antigen level (13.1 ng/ml, α<0. 0001) and over 3-fold higher PAI-1 activity (26.7 AU/ml, α<0. 001) than healthy controls.
Conclusions: Reduced antithrombin III, protein C, protein S activity and excessive activation of the coagulation system with secondary fibrinolytic activity increase were found in patients with recurrent DVT.

Keywords: Antithrombin III, Blood Coagulation Tests, Fibrin Fibrinogen Degradation Products, Fibrinolysis, Phlebography, Plasminogen Activator Inhibitor 1, Platelet Function Tests, Plethysmography, Protein C, Protein S, Recurrence, Risk Factors, Thrombophilia, Tissue Plasminogen Activator, Venous Thrombosis

Add Comment 0 Comments

Editorial

01 April 2025 : Editorial  

Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to Humans

Dinah V. Parums

DOI: 10.12659/MSM.949109

Med Sci Monit 2025; 31:e949109

0:00

In Press

Clinical Research  

Serum Prolidase and Ischemia-Modified Albumin Levels in Neural Tube Defects: A Comparative Study of Myelome...

Med Sci Monit In Press; DOI: 10.12659/MSM.947873  

0:00

Clinical Research  

Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis Patients

Med Sci Monit In Press; DOI: 10.12659/MSM.947630  

Clinical Research  

Longitudinal Evaluation of Metabolic Benefits of Inactivated COVID-19 Vaccination in Diabetic Patients in T...

Med Sci Monit In Press; DOI: 10.12659/MSM.947450  

0:00

Clinical Research  

Impact of Voltage Level on Hospitalization and Mortality in Electrical Injury Cases: A Retrospective Analys...

Med Sci Monit In Press; DOI: 10.12659/MSM.947675  

Most Viewed Current Articles

17 Jan 2024 : Review article   8,000,435

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   702,963

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   30,040

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   23,978

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750